A Virginia bill has been passed by the state legislature allowing the use of the psychedelic mushroom compound psilocybin as a potential medical treatment once a formulation is approved by the Food and Drug Administration. The bill, named Senate Bill 379, allows the state Board of Pharmacy to reschedule psilocbin consistent with federal scheduling once the FDA approves a form of it. The sponsor, Sen. Jennifer Boysko, believes that if there is treatment available, it should be accessed. The measure was introduced as a solution to high veteran suicide rates due to promising clinical studies using psilokins for mental health conditions. The company, Compass Pathways, is currently in the late stages of a clinical trial for a synthetic psilocrin formulation called COMP360, which is intended to treat resistant depression.